Alcobra Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Private, Subsidiary
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 283
- Registration Number
- NCT02477748
- Locations
- 🇺🇸
Richard H Weisler, MD, PA, Raleigh, North Carolina, United States
🇺🇸Institute for Advanced Medical Research, Alpharetta, Georgia, United States
🇺🇸Lake Charles Clinical Trials, Lake Charles, Louisiana, United States
Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects
- Conditions
- ADHD, Predominantly Inattentive Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT02189772
- Locations
- 🇮🇱
Geha Medical Centre, Petah Tiqva, Israel
🇮🇱The Chaim Sheba medical center, Tel Hashomer, Ramat Gan, Israel
🇮🇱Shalvata Mental Health Center, Hod Hasharon, Israel
A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: MG01CI extended-release tablet
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT02126995
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati,, Ohio, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸University of California Davis Pediatrics, Sacramento,, California, United States
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
- Conditions
- ADHDAttention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
- Interventions
- Drug: placeboDrug: MG01CI (1400 mg)
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT02059642
- Locations
- 🇮🇱
ADHD unit Geha MC, Petach Tikva, Israel
🇺🇸Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States
🇺🇸FutureResearch Trials, Austin, Texas, United States
A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT01933997
- Locations
- 🇮🇱
Clinical research center Souraski medical center, Tel Aviv, Israel
Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
- Conditions
- ADHD Predominantly Inattentive Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT01685281
- Locations
- 🇮🇱
Geha Medical Centre, Petah Tiqva, Israel
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01243242
- Locations
- 🇮🇱
ADHD Unit, Geha Mental Health Center, Petah Tikva,, Israel
🇮🇱Cognitive Neurology unit Rambam Health Care Campus, Haifa, Israel
Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT00995085
- Locations
- 🇮🇱
ADHD Unit, Geha MHC, Israel, Petach Tikva, Israel